Peer-reviewed article in journal Clinics in Oncology highlights ability of Biocept's Target Selector™ to detect a key biomarker to qualify breast cancer patients for targeted therapy when tissue biopsy is inconclusive SAN DIEGO , June 18, 2018 /PRNewswire/ -- Biocept, Inc.
Peer-reviewed article in journal, Clinics in Oncology, further supports the clinical utility of Biocept's Target Selector™ platform to aid physicians in the selection of targeted therapy for patients with lung cancer SAN DIEGO , Feb. 5, 2019 /PRNewswire/ -- Biocept, Inc.
Peer-reviewed article in Oncology & Hematology Review highlights capability of Target Selector™ to detect a key biomarker to qualify lung cancer patients for targeted therapy when tissue biopsy is inadequate SAN DIEGO , April 27, 2018 /PRNewswire/ -- Biocept, Inc.
Targeted Lung Panel Now Available with Physician’s Order at Quest’s 2,200 Patient Service Centers Nationwide SECAUCUS, N.J. AND SAN DIEGO – December 1, 2021 – Physicians in the United States can now order the liquid biopsy-based Target Selector™ NGS Lung Panel test directly from Quest Diagnostics
SAN DIEGO , Nov. 17, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that results from a prospective
Companies to take next step following successful completion of feasibility studies PHILADELPHIA & REHOVOT, Israel & SAN DIEGO --(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, and Biocept, Inc.
Real-world retrospective study showed increased sensitivity for CNSide relative to standard cerebral spinal fluid (CSF) cytology in detecting leptomeningeal metastases SAN DIEGO --(BUSINESS WIRE)--Jun. 5, 2023-- Biocept, Inc . (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading provider of
SAN DIEGO , Feb. 23, 2015 (GLOBE NEWSWIRE) -- Biocept , Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced that its blood-based diagnostic, OncoCEE-BR™, was
Target Selector™ platform delivers 90% concordance and capability to rapidly detect EGFR, ALK, BRAF, and ROS1 alterations in non-small cell lung cancer patients
